טוען...
Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
Antibodies targeting the receptor programmed death 1 on T cells have been approved for the treatment of lung cancer. Immune checkpoint inhibitors (ICIs) induce various immune-related adverse events. Life-threatening hematotoxicity can be provoked by ICI therapy. Although ICI-related endocrinopathy a...
שמור ב:
| הוצא לאור ב: | Respir Med Case Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6557745/ https://ncbi.nlm.nih.gov/pubmed/31198679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2019.100871 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|